-
Merck reports phase 3 KEYNOTE─B96 trial meets secondary endpoint of OS in all comers population of patients with platinum─resistant recurrent ovarian cancer
18 Oct 2025 07:55 GMT
… -Ovarian01 trial in collaboration with Daiichi Sankyo evaluating raludotatug deruxtecan (R-DXd … discovered by Daiichi Sankyo and is being jointly developed by Daiichi Sankyo and Merck …
-
<![CDATA[Osimertinib Plus Chemo Demonstrates OS Benefit in EGFR+ NSCLC With Poor Prognostic Factors]]>
18 Oct 2025 01:16 GMT
… , Takeda, PUMA, Astellas Pharmaceuticals, and Daiichi Sankyo. He also is the co …
-
<![CDATA[Perioperative Durvalumab/NAT Chemo Does Not Improve HRQOL in MIBC]]>
17 Oct 2025 21:12 GMT
… , Astellas, Pfizer, Seagen, Janssen, and Daiichi Sankyo.
References
1. van der Heijden …
-
<![CDATA[Frontline Alectinib Upholds OS Benefit in Advanced ALK+ NSCLC]]>
17 Oct 2025 21:12 GMT
… -financial support from AbbVie Inc., Daiichi Sankyo, and MIRXES; personal fees including …
-
<![CDATA[Sevabertinib Monotherapy Shows Robust Response in HER2-Mutant NSCLC]]>
17 Oct 2025 20:44 GMT
… , Blueprint Medicines Corporation, Boehringer Ingelheim, Daiichi Sankyo Company, Eli Lilly and Company …
-
<![CDATA[Durvalumab Plus FLOT Improves OS in G/GEJ Adenocarcinoma]]>
17 Oct 2025 20:45 GMT
… Biotech, Cartography Biosciences, Chugai Pharmaceutical, Daiichi Sankyo Company, Eli Lilly and Company …
-
<![CDATA[Saruparib Plus ARPI Shows Promising Efficacy in Metastatic Prostate Cancer]]>
17 Oct 2025 20:44 GMT
… , Amgen, Noxopharm, Merck Sharpe Dohme, Daiichi Sankyo, Arvinas; Financial Interests, Personal, Other …
-
<![CDATA[Perioperative Durvalumab Maintains HRQOL in MIBC Treatment]]>
17 Oct 2025 20:44 GMT
… , Astellas, Pfizer, Seagen, Janssen, and Daiichi Sankyo.
REFERENCES:
1. van der Heijden …
-
<![CDATA[Adjuvant Nivolumab Generates Long-Term DFS Benefit in Resected MIUC]]>
17 Oct 2025 17:32 GMT
… Therapeutics, Bristol Myers Squibb, Curis, Daiichi Sankyo, Dragonfly Therapeutics, EMD Serono, Fujifilm …
-
Merck's Keytruda follows primary endpoint win in ovarian cancer study with OS triumph
17 Oct 2025 01:05 GMT
… . Merck is additionally testing a Daiichi Sankyo-partnered antibody-drug conjugate in …